Cellular Biomedicine Group (CBMG) Issues Encouraging Update on CD30-Directed CAR-T Cell Therapy Phase 1
Tweet Send to a Friend
Cellular Biomedicine Group (NASDAQ: CBMG) announced encouraging clinical data from its Chimeric Antigen Receptor (CAR-T) CD30-positive Hodgkin's lymphoma immuno-oncology clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE